Last updated: 2026-09-09 08:42:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Disc Medicine, Inc. (IRON) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $77.40, with a market capitalization of $3.04B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $40.00 to $99.50. This page covers its latest market performance, valuation, price trends and company information.
$3.04B | |
$77.40 | |
$99.50 | |
$15.00 | |
$76.84 | |
13.00 | |
526.29K | |
-- | |
$99.50 | |
$40.00 | |
-- | |
-- |
Disc Medicine, Inc. (IRON) is trading at $77.40 in pre-market trading as of 2026-09-09 08:05:00, up 0.73% ($0.56) from the previous close of $76.84
Pre-market trading shows how investors are pricing IRON before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Disc Medicine, Inc. (IRON) moved from $80.03 to $77.40, representing a decline of 3.29% ($2.63).
The stock traded between $74.50 and $82.70 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 541.67 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 62.9%
IRON is currently trading at $77.40, placing it 62.9% of the way from its 52-week low of $40.00 to its 52-week high of $99.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 165 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Disc Medicine, Inc. (IRON) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.